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Chapter




Atrial Fibrillation (AF) is an early and common occurrence during septic 
shock, accounting for 25–30% of admissions. Conventional cardiovascular risk 
factors do not generally increase its incidence, especially in cases of new-onset AF. 
Inflammation during the sepsis process has been postulated as a possible trigger. 
Detrimental effects of AF result in prognosis worsening, even when the probability 
for a negative outcome has been adjusted for severity of illness. New-onset AF 
(NOAF) has been associated with greater mortality rate than preexisting chronic 
AF. Early cardioversion has not uniformly improved hospital outcomes. In this 
review, the incidence, prognosis and management of AF in septic shock patients are 
summarized.
Keywords: atrial fibrillation, septic shock, sepsis, antiarrhythmic therapy, 
cardioversion, critical care
1. Introduction
The term sepsis derives from ancient Greek “sêpsis” (“putrefaction” or “decay of 
organic matter”) and was first used in a medical context in Homer’s Iliad more than 
2700 years ago. Currently, sepsis is defined as a life-threatening organ dysfunction 
due to a dysregulated host response to infection [1]. Since 2016, the updated opera-
tive definition of sepsis no longer considers the presence of systemic inflammatory 
response syndrome, but requires an infection plus organ dysfunction indicated by 
an acute change in Sequential Organ Failure Assessment (SOFA) [2] of at least two 
points (see Table 1). Septic shock is defined as sepsis plus circulatory failure with 
increased risk of death, indicated by hypotension requiring vasopressor therapy to 
maintain a mean arterial pressure (MAP) 65 mmHg or greater and a serum lactate 
of greater than 2 mmol/L despite adequate fluid resuscitation [3]. Other indices of 
tissue hypoperfusion (e.g. altered mental status, oliguria, delayed capillary refill) 
are acceptable alternatives whenever serum lactate determination is not available.
In high-income countries, sepsis represents approximately 6% of adult hospital-
izations and 10–37% of intensive care unit (ICU) admissions. Mortality estimates 
from sepsis and septic shock vary widely, rounding 15% and 22% respectively [4]. 
In low-income regions, sepsis and septic shock predictably carry an even higher 
mortality, up to 50% [5].
Generally speaking, atrial fibrillation (AF) is the most frequently found cardiac 
arrhythmia in the ICU setting. Previously known AF is significantly prevalent 
among older patients with chronic conditions who are at risk for critical illness. 
New-onset AF (NOAF), on the other hand, is frequently triggered by accelerated 
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0 1 2 3 4
Respiration PaO2/FIO2, mmHg (kPa) ≥400 (53.3) <400 (53.3) <300 (40) <200 (26.7) with respiratory support <100 (13.3) with respiratory support
Coagulation platelets, ×103 μL−1 ≥150 <150 <100 <50 <20
Liver bilirubin, mg dL−1 (μmol L−1) <1.2 (20) 1.2–1.9 (20–32) 2.0–5.9 (33–101) 6.0–11.9 (102–204) >120 (204)
Cardiovascular MAP 
≥70 mmHg
MAP<70 mmHg Dopamine<5 or 
dobutamine (any dose)a
Dopamine 5.1–15 or epinephrine 
≤0.1 or norepinephrine ≤0.1a
Dopamine >15 or epinephrine >0.1 
or norepinephrine >0.1a
Central nervous system (CNS)
Glasgow Coma Scale scoreb 15 13–14 10–12 6–9 <6
Renal creatinine, mg dL−1 







Urine output, mL per day <500 <200
FIO2, fraction of inspired oxygen; MAP, mean arterial pressure; PaO2, partial pressure of oxygen.
aCatecholamine doses are given as μgkg−1 min−1 for at least 1 h.
bGlasgow Coma Scale scores range from 3 to 15; higher score indicates belter neurological function.
Table 1. 
Sequential organ failure assessment (SOFA) score [2].
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atrial remodeling and by concomitant stressors during critical illness, such as 
electrolyte imbalances and use of vasopressor drugs [6].
In this narrative review, the pathogenesis, risk factors, incidence, prognosis and 
management of AF in septic shock patients are summarized.
2. Pathogenesis
The negative effects of sepsis on the heart are not limited to the contractile 
function and ventricular relaxation, but also affect the electric function. Although 
the precise mechanisms remain to be elucidated, inflammation seems to play an 
important role. The electrical instability of cardiomyocytes in patients with sepsis 
has been considered to be due to the use of vasopressor drugs and the presence of 
electrolyte disturbances. However, according to recent findings, atrial fibrillation 
(AF) could be the result of the necrosis and fibrosis induced by inflammation [7, 8]. 
These alterations are supposed to be able to trigger an arrhythmia due to a fluctua-
tion in the myocardial cells’ membrane potential [9].
The development of NOAF in septic shock patients depends upon the presence 
of an arrhythmogenic substrate, the trigger factors and the modulation factors such 
as autonomic nervous system or inflammation. Triggered activity has been shown 
in the musculature of the atrium. An imbalance between sympathetic and vagal 
tone leading to a reduction of heart rate variability has been proposed as an expla-
nation for the development of NOAF in septic patients [10]. Vagal stimulation nor-
mally attenuates the inflammatory response [11]. In human atrial cardiomyocytes, 
partial blockage of the I(f) ‘funny’ pacemaker current has been observed after 
exposition to gram-negative bacteria endotoxin [12], which may contribute to a 
reduced responsiveness to both sympathetic and vagal autonomic stimuli (the name 
“funny current” arose because of its numerous unusual characteristics, including 
the mixed Na + and K+ current permeability, activation on hyperpolarization, and 
Figure 1. 
Schematized transmembrane action potential of sinus node (pacemaker) cells. The black line shows normal 
slope in sinus rhythm. During gram-negative bacteria induced-sepsis, it has been shown I(f) current blockage, 
which results in an increased phase 4 slope, triggering sinus tachycardia and facilitating AF onset (red line) [12].
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slow activation and deactivation kinetics [13]) (see Figure 1). This would result in a 
high heart rate output, which is commonly observed in septic patients. Unopposed 
sustained tachycardia during the will further increase calcium influx through 
L-type Ca2+ channels, which leads to marked shortening of the atrial refractory 
period and action potential duration (Figure 1) and elicit triggered activity, hence 
facilitating the onset of AF [14, 15] (see Figure 2). This process has been shown to 
be further enhanced due to beta-adrenergic stimulation after endotoxin application 
[16], which increases channel activity by prolonging the open time and shortening 
the close time of Ca2+ channel. These findings might explain the high sensitivity 
of cardiac pacemaker cells to positive inotropic effect of adrenergic stimulation 
and most likely development of new AF episode especially in the early stages of 
sepsis [17].
3. Risk factors
Sepsis itself is a strong risk factor for NOAF in the critical care setting. An exten-
sive retrospective population-based cohort analysis by Walkey et al. revealed that 
compared to those without severe sepsis, patients with severe sepsis (n = 49,082) 
exhibited a significantly increased risk of NOAF (odds ratio (OR), 6.82; 95% confi-
dence interval (CI), 6.54–7.11; P < 0.001) [18]. Multiple studies have been shown that 
the classic risk factors for the development of chronic atrial fibrillation in the general 
population may differ from those present in septic patients with NOAF. Risk factors 
for the occurrence of NOAF in septic patients include conditions that are not related 
to chronic cardiovascular disease, such as increased number of acute organ failures/
dysfunction, mechanical ventilation, increased comorbidities, and use of pulmonary 
artery catheterization [18–22]. NOAF has been also associated with lower EF, older 
age, higher level of troponin-HS and NT-pro-BNP and longer QRS duration.
Figure 2. 
Schematized transmembrane action potential of atrial myocytes in normal and septic animals. The orange line 
indicates how sepsis decrease phase 2 (plateau phase) duration and leads to decrease in APD (action potential 
duration). This is due to a decrease in influx of calcium through the voltage-dependent L-channels, which is 
at least in part caused by sepsis-induced tachycardia. The decrease in APD (and hence in the atrial refractory 
period) has been proposed to effectively trigger AF [15].
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Sepsis due to bacterial pneumonia has been associated with a high risk of 
developing NOAF, while sepsis due to gastrointestinal infections has been related to 
AF recurrence with worse long-term prognosis [23]. It has been hypothesized that 
the type and severity of infection could have an impact on the atrial remodeling and 
the variety of cytokine expression during sepsis. Current evidence suggests that the 
severity of the inflammatory response in critically ill patients is associated with a 
higher risk of NOAF, and septic shock patients have in general a heightened prob-
ability of developing NOAF than patients with other acute critical illnesses after 
adjustment for underlying risk factors [21].
In a systematic review that included 11 studies, Kuipers et al. [19] identified 
independent risk factors with a high level of evidence for NOAF in septic patients. 
White race, organ failure and pulmonary catheter use were moderately associ-
ated with NOAF development, while there was a weak association with age and 
respiratory tract infection. On the other hand, history of diabetes and urinary 
tract infections were found to be weak protective factors. In other studies, mark-
ers of illness severity (such as the presence of organ failure and shock) as well as 
several critical care interventions were associated with an increased risk of NOAF 
in septic patients. Known risk factors for chronic or paroxysmal AF in the general 
population, such as advanced age, white race, male gender, obesity and (ischemic) 
heart failure, were in some studies also associated with the development of AF 
during sepsis [24, 25]. Specific electrocardiographic or echocardiographic features 
of AF such as P-wave duration or left atrial area, remain to be studied in septic 
shock patients, although both factors are known to predict the occurrence of AF in 
the general population [26, 27].
Data regarding risk factors for the occurrence of NOAF in septic shock patients 
is more limited. Guenancia et al. [26] found that NOAF patients were older and 
had higher levels of cardiac biomarkers (troponin (p < 0.01) and NT-pro-BNP 
(p = 0.03)), lower left ventricular ejection fraction (LVEF), longer duration of the 
QRS complex and more nonsustained supraventricular arrhythmias (< 30 seconds) 
on day 1 than patients who maintained sinus rhythm. Age (OR: 1.06; p = 0.01) and 
LVEF <45% (OR: 13.01, p = 0.03) were associated with NOAF in their multivariate 
analysis.
4. Incidence
Atrial fibrillation is a common occurrence in patients with sepsis and septic 
shock, and its incidence varies widely among investigators. This may be due to the 
different criteria used to define sepsis and septic shock, or the method used for the 
diagnosis of AF [28]. In the aforementioned systematic review, Kuipers et al. [19] 
showed that the mean incidence of new-onset AF was 8% in patients with sepsis 
and 23% in patients with septic shock. The authors of that study also observed a 
significant increase in ICU length of stay in this group of patients. In a large study 
conducted by Walkey et al. [21], which retrospectively analyzed data from over 
60,000 patients admitted for sepsis, the investigators found an overall incidence of 
AF during sepsis of 25.5%. This number rose to 31.6% when considering only the 
ICU population.
To date, there have been relatively few published prospective investigations 
regarding the incidence of AF in septic shock patients, although there is more 
available information about the general topic of AF in septic patients. Seguin et 
al. [29] found AF developed in 24 patients (5.3%) of 460 patients admitted to the 
surgical intensive care unit and followed prospectively during a 6-month period. 
They reported that 29.2% (7 of 23 patients) of septic shock patients developed AF. 
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They concluded the presence of shock (especially septic shock) appeared to be an 
independent risk factor of AF in their cohort. It has to be recognized, however, that 
the operative definition of septic shock used at that time, the one proposed by Bone 
et al. [30], has since been substantially modified.
Steinberg et al. [28] published recently a one-year observational prospective 
study of 27 septic shock patients. Their aim was to evaluate the incidence of AF, and 
the mortality rate of patients with AF versus patients that maintained sinus rhythm. 
Nine (33%) patients developed AF during the first 72 hours. At admission and 
at 72 hours, SOFA was statistically higher in the patients with AF (p = 0.012 and 
p = 0.002, respectively).
In a single-center study, Meierhenrich et al. [31] prospectively studied all 
patients with NOAF and all patients suffering from septic shock in ICU during a 
13 month period. Patients with preexisting chronic AF were excluded from their 
analysis. They found 23 out of the 50 patients with septic shock (46%) developed 
NOAF, compared to an overall incidence (septic and non-septic patients taken into 
account) of NOAF of 7.8% (49/629). The same aforementioned limitation in septic 
shock definition applies to this data.
Guenancia et al. [26] conducted a single-center prospective, observational study 
on patients with septic shock, and they found an incidence of new-onset AF of 44% 
(29 of 66 patients). Noteworthy, a 34% of new-onset AF would not be diagnosed 
without Holter ECG monitoring (silent AF).
More recently—and using an updated definition of septic shock—Rabie et al. 
[32] prospectively studied 100 septic shock patients, one of the largest series ever 
published. All patients were continuously monitored by three/five-lead monitor 
with arrhythmia detection algorithms, alarms, and Holter recording capabilities 
throughout the ICU stay. The investigators found the development of NOAF in 29 
(29%), of which 22 (75,8%) patients had a single occurrence and 7 (24,2%) had 
recurrent AF during their ICU stay.
5. Prognosis
Whether NOAF acts as a surrogate marker for increased illness severity and 
subsequently poor prognosis in sepsis or whether it directly contributes to mortal-
ity and poor outcomes is not entirely clear. As stated before, the sepsis state can 
trigger AF mainly because of the combined mechanisms of inflammation, surge in 
catecholamines, and direct and indirect myocardial injury, and the poor prognosis 
noted whenever AF develop in critically ill patients may be the consequence of the 
presence of these factors.
In a retrospective analysis, Walkey et al. [33] found that patients with NOAF 
during a hospitalization for sepsis showed a higher five-year risk of hospitalization 
for heart failure (11.2% vs. 8.2%; HR, 1.25; 95% CI, 1.16–1.34), ischemic stroke 
(5.3% vs. 4.7%; HR, 1.22; 95% CI, 1.15–1.47), and death (74.8% vs. 72.1%; HR, 1.04; 
95% CI, 1.01–1.07) than patients who did not develop NOAF.
Specific prospective data regarding the prognosis of NOAF in septic shock 
patients is also sparse. In a small series of 27 septic shock patients followed prospec-
tively for one year, Steinberg et al. [28] reported that mortality was higher in AF 
patients (66%) than in patients in sinus ryhtm (11%) (p = 0.006). Age, rhythm and 
noradrenaline dosage were univariate predictors of total mortality. In the afore-
mentioned study of Meierhenrich et al. [31], mortality in septic shock patients with 
NOAF was 44% compared with 22% in septic shock patients with maintained sinus 
rhythm (p = 0.14). The average length of ICU stay was shown to be increased in 
patients with NOAF (30 versus 17 days, p = 0.017). Failure to achieve sinus rhythm 
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restoration was associated with greater ICU mortality (71.4% vs. 21.4%, p = 0.015). 
After two years, the investigators observed a statistically nonsignificant increase in 
mortality in septic shock patients with NOAF (p = 0.075).
In a larger prospective series, Rabie et al. [32] found that mortality in patients 
with single AF attacks were not statistically higher than non-AF patients 
(p = 0.143). However, recurrent attacks of AF had significantly higher mortality 
than non-AF or single AF attack (p < 0.05). Recurrent AF was associated with 
increased length of UCI stay (21.6 ± 7.2 vs. 12.9 ± 7.3 days, p = 0.004).
6. Management
When considering use of antiarrhythmic drugs or applying cardioversion in 
septic patients with atrial fibrillation and hemodynamic instability, causative fac-
tors must in parallel be addressed and corrected when feasible [34]. Since diastolic 
dysfunction is highly prevalent in ICU patients and is also an independent predic-
tor of mortality [35], both excessive or insufficient fluid resuscitation should be 
avoided. For example, the so-called Early Goal Directed Therapy has shown mar-
ginal benefit [36] while heightening the risk of fluid overload and the overuse of 
betaadrenergic stimulant drugs to achieve central venous saturation above 65%. The 
resulting high cardiac output constitutes an arrhythmogenic setting. Interestingly, 
ceasing beta-stimulation and administering low-dose betablockers with concomi-
tant preload correction has led to a dramatic decrease in mortality [37]. While the 
use of vasopressors in septic shock is recommended in early septic shock, preload 
assessment and timely administration of vasopressin can assist in diminishing 
the requirement of catecholaminergic drugs and consequently lower the risk of 
arrhythmia. Suboptimal volume replacement, on the other hand, carries the risk of 
higher sympathetic tone and consequent down-to regulation of adrenergic recep-
tors which in turns leads to requirement of greater doses of vasopressor drugs. 
Hence, both conditions, namely fluid overload and hypovolaemia, are triggering 
factors for developing arrhythmias.
Electrolyte disturbances, which are commonplace in ICU patients, should 
be likewise identified and promptly corrected. Hypokalemia and hyperkalemia 
triggers supraventricular and ventricular arrhythmias. If the potassium level does 
not respond to adequate supplementation, magnesium levels must be assessed and 
corrected, since severe hypomagnesemia prevents the potassium level being cor-
rected. It has been shown that septic patients tend to have lower serum magnesium 
levels when compared to nonseptic patients [38, 39]. Hypophosphatemia is associ-
ated with decreased myocardial contractility and a higher incidence of arrhythmia 
[40], and the correction of phosphorus level has been shown to prevent it [41]. 
Hypocalcemia may also be associated with arrhythmias [42, 43], although the data 
in septic patients is scarce.
Right ventricular dysfunction may cause acute cor pulmonale and supraventric-
ular arrhythmias [44]. Instituting aggressive modalities of mechanical ventilation 
in septic patients with acute distress respiratory syndrome as an attempt to recruit 
consolidated lungs may trigger an increase in right ventricular afterload, with the 
consequent development of NOAF. Gradual opening of the consolidated lungs in 
a prone position [45] guided by periodic chest ultrasound and echocardiographic 
assessment may prevent the onset of supraventricular arrhythmias.
Guidelines for management of AF [46] do not usually apply readily to critically 
ill patients, since NOAF in patients treated on an ICU differs from AF in patients 
in the community in terms of causes of rhythm disturbance [47], and appropriate 
management [48].
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6.1 Electrical therapy
Synchronized direct current cardioversion (SDCC) should be employed for 
patients with hemodynamic instability related to the arrhythmia, even though the 
probability of remaining in sinus rhythm may be low. In critically ill patients, SDCC 
has been investigated in few studies. The reported efficacy is generally low, ranging 
from 26.9% and 35.1% [49, 50]. Mayr et al. reported successful electrical cardiover-
sion at one hour after the attempt in 13/37 (35.1%) ICU patients with NOAF. After 
24 hours, six of these 37 patients (13.5%) remained in sinus rhythm. An additional 
study evaluating the efficacy of SDCC reported sinus rhythm restoration for at least 
24 hours in 7/26 (26.9%) patients. Of note, 18 of these patients had received amio-
darone prior to or during electrical cardioversion [49].
In septic shock patients with NOAF, there is lack of data on effectiveness. In a 
small series [28], SDCC was attempted in five patients due to hemodynamic insta-
bility. In three patients, the procedure was not effective, whereas, in one patient, 
sinus rhythm was restored. However, AF recurred shortly afterwards; and in one 
case, a stable sinus rhythm was obtained. The effectiveness of electrical therapy 
may be improved by concomitant antiarrhythmic medication. When electrically 
cardioverting 24% of septic shock patients on amiodarone and 36% on propafe-
none, the overall rate of sinus rhythm maintenance was significant (74% and 89%, 
respectively) [51]. After an initially successful cardioversion, failure to remain in 
sinus rhythm may signal a poor prognosis.
6.2 Antiarrhythmic pharmacological therapy
6.2.1 Amiodarone
Amiodarone is a Vaughan-Williams class III antiarrhythmic drug that is frequently 
used to treat atrial fibrillation, both in community and ICU settings. It is currently 
approved for cardioversion of atrial fibrillation (Class I, level of evidence A) [52]. It 
is a highly lipophilic compound with a long half life, and it is eliminated by hepatic 
metabolism and not by dialysis [53]. Being one of the few antiarrhythmic drugs that 
does not affect significantly the left ventricular ejection fraction (LVEF), its use is 
however limited by the occasional occurrence of systemic hypotension and because 
of its relatively highly toxic profile, including thyroid, lung and liver dysfunction 
among other detrimental effects (eg, corneal microdeposits, skin discoloration and 
neuropathies).
Amiodarone success in terms of rhythm control in sepsis patients varies widely, 
from 30% [54] to 95% [55], although rates of sustained sinus rhythm after cardio-
version are substantially lower. Comparative observational studies in ICU septic 
patients have shown that amiodarone achieved lower rates of rhythm control than 
beta-blockers, magnesium and calcium channel blockers [51, 54, 56].
Specific data on amiodarone effectiveness in septic shock patients is scant. Balik 
et al. [51] showed in a recent study on septic shock and supraventricular arrhyth-
mias (AF being the most frequent encountered) that amiodarone was the drug of 
choice in 76% of patients, likely due to the hemodynamic instability of patients 
in septic shock on vasoactive agents. Restoration to sinus rhythm was achieved in 
74% patients while 23.7% of them required additional electrical cardioversion. 
The median total dose of amiodarone was 3.0 (1.8–4.6) g, given by infusion over 4 
(2–6) days with a median of 1.4 (0.9–1.8) g during the first day. Due to its limited 
efficacy to cardiovert and to maintain sinus rhythm (74%), the patients with a 
persisting arrhythmia were often switched to propafenone. Interestingly, in this 
study, successfully cardioverted patients (with either amiodarone, propafenone or 
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metoprolol) or those having chronic AF demonstrated not significantly lower ICU 
and 28-day, and 12-month mortalities compared to patients remaining in an acute 
onset arrhythmia.
In a retrospective review of adult medical or surgical ICU patients with septic 
shock and NOAF that received amiodarone (n = 239), Betthauser et al. [57] found 
that exposure to more than or equal to 2700 mg of amiodarone was positively corre-
lated with longer ICU length of stay. The same investigators found that compared to 
non-septic shock patients, septic shock patients did not show significant difference 
in hemodynamic deterioration within 72 hours of intravenous amiodarone adminis-
tration. Of 105 patients surviving hospital discharge, 29% continued receiving oral 
amiodarone at discharge.
6.2.2 Propafenone
Propafenone is a Vaughan-Williams class IC antiarrhythmic drug with some 
(but clinically limited) beta-blocking activity as a result of a structural similarity to 
beta-adrenoceptor antagonists [58]. Propafenone is currently approved and used 
frequently for cardioversion of atrial fibrillation (Class I, level of evidence A) [52]. 
However, since CAST (the Cardiac Arrhythmia Suppression Trial) [59] revealed that 
class IC antiarrhythmic drugs flecainide and encainide could increase the mortality 
risk when administered to patients with ventricular arrhythmias and coronary artery 
disease with significant left ventricular systolic dysfunction, current guidelines have 
restricted the recommendation of this class of drugs (including propafenone) to 
patients with NOAF who do not have structural heart disease [52].
The aforementioned study by Balik et al. [51], suggests that propafenone could 
be a drug of choice in septic shock patients with normal to moderately reduced 
LVEF. Propafenone was used in septic shock patients with NOAF as a primary anti-
arrhythmic in 17.5% of patients, but this figure rises to 33% if one takes into account 
the patients who were not able to cardiovert and maintain a sinus rhythm on amio-
darone and then received propafenone. The observed cardioversion success rate 
was 86.1% at 24 h, although 35.5% needed additional SDCC to restore sinus rhythm. 
The success of cardioversion was significantly higher with propafenone than with 
amiodarone and almost the same as metoprolol (93%). The average propafenone 
dose was 670 (460–700) mg/day. Compared with amiodarone, propafenone use did 
not result in significantly lower ICU and 28-day mortalities, but was associated with 
a 12-month mortality benefit, although patients in propafenone group tended to 
have better LVFE at baseline and lower dose of vasopressor drugs (e.g., norepineph-
rine), likely reflecting more severe compromise of septic shock in the amiodarone 
group [34].
6.2.3 Beta-adrenergic blockers
Current guidelines recommend beta-blockers as first-choice drugs to control 
heart rate in AF patients with LVEF >40% (class I, level of evidence B) [52].
Autonomic dysfunction in septic shock may be accompanied by extreme 
tachycardia and high cardiac output. Tachycardia increases cardiac workload and 
myocardial oxygen consumption. In addition, shortening of diastolic relaxation 
time and impairment of diastolic function further affect coronary perfusion, 
contributing to a lower ischemic threshold. Although norepinephrine is the current 
recommended mainstay of treatment for sepsis-related hypotension, excessive 
adrenergic stress has multiple adverse effects including direct myocardial damage 
(e.g., takotsubo or stress cardiomyopathy and tachyarrhythmias), insulin resis-
tance, thrombogenicity, immunosuppression, and enhanced bacterial growth [60]. 
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Taken together, these mechanisms contribute to worsening of septic myocardial 
dysfunction and increased mortality [61].
The use of beta-adrenergic blockers has been proposed to mitigate the persis-
tent sympathetic stimulation in septic shock patients, and this mechanism may in 
part be responsible of the observed improvement in prognosis. The production of 
cytokines may also be reduced with the consequent improvement in the metabolic 
dysregulation by means of reducing protein catabolism and by inhibiting gluco-
neogenesis [62]. On the other hand, using beta-blockers in septic shock patients is 
not without risks. Many patients with septic shock are already being treated with 
vasopressor and inotropic drugs, and treating them with beta-blockers can exacer-
bate hypotension and bradycardia promoting further hemodynamic instability [63].
In order to reduce the unnecessary load of catecholamines and the stimulation 
of their receptors, an easily titratable beta-blocker (e.g. esmolol or landiolol), may 
be safe in those patients who require vasopressor drugs in parallel for low systemic 
vascular resistance and hypotension. In an open-label, randomized single-center 
study (n = 154) by Morelli et al. [64], septic shock patients were assigned to receive 
a continuous infusion of esmolol titrated to maintain heart rate between 80/min 
and 94/min versus standard treatment. It was not specified how many of those 
patients had atrial fibrillation, so its main interest in this discussion relates to its 
tolerability, since traditionally it has been feared that betablockage in septic patients 
could result in hemodynamic deterioration. Nonetheless, the mean arterial pres-
sure was maintained despite a marked reduction in norepinephrine requirements 
in the esmolol group. Also, stroke volume, systemic vascular resistance, and left 
ventricular stroke work indices were increased in the esmolol group. Noteworthy, it 
was shown that 28-day mortality was 49.4% in the esmolol group vs. 80.5% in the 
control group (adjusted hazard ratio, 0.39; 95% CI, 0.26 to 0.59; p < 0.001). These 
findings suggest that lowering of heart rate by esmolol allows better ventricular 
filling during diastole, hence improving stroke volume and thereby improving the 
efficiency of myocardial work and oxygen consumption.
Metoprolol is also well tolerated in septic shock patients with supraventricular 
arrhythmias. In septic shock patients with NOAF treated with intravenous meto-
prolol, Balik et al. [51] found that sinus rhythm was achieved in 92.3% patients with 
no additional electrical cardioversion. The median length of treatment was 5 (2–9) 
days, while the median intravenous metoprolol dose was 84 (48–120) mg/day.
A relatively new beta-blocker with high selectivity for beta1 receptors and a 
half-life of only 4 minutes, landiolol, has also been shown to be well tolerated in 
the critically ill for its limited negative inotropic effect and limited impact on blood 
pressure, as different Japanese teams of investigators have reported [65–67]. The 
use of low doses (5–10 mcg/kg/min) of landiolol is usually sufficient for the cardio-
version of AF compared to controls. In sinus tachycardia, landiolol may prevent the 
occurrence of arrhythmias using an even lower dose (3–5 mcg/kg/min). In a multi-
center, open-label, randomized controlled trial at 54 hospitals in Japan, in which 76 
patients with sepsis or septic shock received intravenous landiolol and 75 patients 
were assigned to the control group, Kakihana et al. [68] found that Landiolol 
resulted in significantly more patients with sepsis-related tachyarrhythmia (55% 
vs. 33%, p = 0.031) achieving a heart rate of 60–94 bpm at 24 h and significantly 
reduced the incidence of new-onset arrhythmia. The investigators report that 
landiolol was also well tolerated, but should be used under appropriate monitoring 
of blood pressure and heart rate owing to the risk of hypotension in patients with 
sepsis and septic shock.
Balik et al. [34], based on studies on tachycardic patients with septic shock 
requiring catecholamine administration suggest the benefit of slowing heart rate by 
approximately 20%, but also warn that lowering heart rate below 100 per minute 
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by means of betablockage may result in a cardiac output inadequate to meet the 
systemic oxygen demands in septic shock. Appropriately powered, randomized, 
controlled multicenter trials are required to further clarify the role of beta-blockers 
in septic shock patients with NOAF.
6.2.4 Digoxin
Digoxin and other cardiac glycosides have been long used to treat patients with 
heart failure and cardiac arrhythmias, atrial fibrillation among the latter. However, 
in the last couple of decades, various clinical trials have resulted in limiting the role 
of digoxin in the management of atrial fibrillation [52]. Digoxin acts at a cellular 
level by inhibiting the sodium-potassium pump, increasing the calcium availability 
to the contractile apparatus. This results in an increase in cardiac contractility and 
slowing of cardiac conduction through the atrioventricular node [69].
There is paucity of data regarding the use of digoxin in septic shock patients 
with NOAF. In a retrospective cohort study of ICU patients (n = 38,159) by Quian et 
al. [70], the investigators found an incidence of NOAF rounding 9%. After adjust-
ing for multiple variables, they found that in patients with NOAF the use of digoxin 
was associated with an increased risk of 90-day mortality (hazard ratio 1.23, 95% 
CI 1.10–1.39, p < 0.001), although the proportion of sepsis patients in this popula-
tion was not specified.
6.2.5 Anticoagulation therapy
While many clinical trials have shown that warfarin therapy reduces the risk 
of thromboembolic complications in patients with AF, it has not been unequivo-
cally proved that oral anticoagulants provide similar benefits in critically ill septic 
patients with AF without carrying a significant bleeding risk. So, a common 
dilemma arises when deciding which septic patients with AF should receive antico-
agulation therapy [71]. Walkey et al. [72] studied the practice patterns of anticoagu-
lation in 38,582 septic patients with AF. They found that more than a third (35.3%) 
of the patients were anticoagulated with intravenous heparin or subcutaneous 
enoxaparin, while the rest of the patients did not receive anticoagulants. In those 
who did, significant bleeding was more frequently observed (8.6% vs. 7,2%, RR 
1.21). Interestingly, there was no significant difference in the risk of ischemic stroke 
between anticoagulated and non-anticoagulated patients (1.4% vs. 1.3%, RR 0.94, 
CI 0.78–1.12). Furthermore, there was no difference in the risk of ischemic stroke 
between patients with preexistent AF and those with NOAF (RR, 1,12).
In a retrospective observational study to assess the incidence of stroke and 
anticoagulation-related complications (e.g., bleeding, heparin-induced thrombo-
cytopenia) in AF patients with severe sepsis (n = 115), Darwish et al. [71] found 
no statistically significant difference in survival rates during their hospitalization 
(66.2% [53/80] in the non-anticoagulated group versus 74.3% (26/35) in the anti-
coagulated group, P = 0.392). There were no reports of strokes in either arm of the 
study, but this finding is at least in part explained by the small number of patients 
and the short period of time used for assessment. Up to date, prospective, compara-
tive robust evidence for anticoagulation in septic shock patients is lacking.
6.2.6 Corticosteroid therapy
Due to its anti-inflammatory properties, low-dose hydrocortisone has been 
frequently used to achieve shock reversal and better outcomes in patients with 
septic shock [73]. However, after extensive review of the available evidence, the 
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Surviving Sepsis Campaign’s guidelines restricted the use hydrocortisone in shock 
septic patients only when fluid resuscitation and vasopressor drugs failed to restore 
hemodynamic stability [74]. In a recent multicenter, prospective nonrandomized 
observational study in 261 septic shock patients, Launey et al. [75], a atrial fibrilla-
tion developed in 33 (24%) and 24 (19%) of no-hydrocortisone patients and hydro-
cortisone patients, respectively. In the weighted sample, the proportion of patients 
who developed AF was 28.8% in the nohydrocortisone group and 16.8% in the 
hydrocortisone group (difference: 11.9%; 95% confidence interval: 23.4% to 0.5%; 
p = 0.04), noting that patients who received hydrocortisone were more severely ill 
than those who did not receive hydrocortisone. Investigators conclude that low-dose 
hydrocortisone was associated with a lower risk of developing AF during the acute 
phase, although serious risk of bias due to missing covariates in the propensity score 
matching has to be taken into account.
7. Conclusions
AF during septic shock has been insufficiently studied. This has led to relevant 
uncertainties regarding its etiology, pathophysiology and appropriate management. 
Risk factors for chronic AF and NOAF frequently differ, and the unique patho-
physiology of NOAF remains to be fully elucidated. Despite of a high probability 
of successful cardioversion achieved by pharmacological or electrical means, these 
treatment modalities have shown modest efficacy in affecting the medium and 
long-term prognosis of septic shock patients with AF. The benefits of anticoagula-
tion in shock septic patients with AF have not been firmly established, while the 
risk of bleeding is increased in septic patients. Evidence-based guidelines and even 
expert consensus documents on the subject of NOAF management are lacking. 
Properly designed multicenter, prospective randomized trials are needed to clarify 
these questions.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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